Navigation Links
ThermoGenesis Announces AABB Accreditation for Cord Blood Products Customer in China
Date:3/29/2012

RANCHO CORDOVA, Calif., March 29, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that its customer Beike Biotechnology Co., Ltd. (Beike) has become the first company in China to receive accreditation from the AABB (formerly the American Association of Blood Banks). AABB is an international, not-for-profit association representing nearly 2,000 institutions and 8,000 individuals involved in the fields of transfusion medicine and cellular therapies.

A leading stem cell and regenerative medicine company in China, Beike will be using ThermoGenesis' AXP® AutoXpress® (AXP) and BioArchive® Systems for the processing and storage of stem cells from cord blood. The Company expects the AXP device to receive registration approval in China during the current year.

Beike produces a full line of products derived from umbilical cord tissue, cord blood and bone marrow stem cells. It also operates three stand-alone cord blood processing and storage facilities, 18 specialized laboratories processing cord blood collection, five stem cell banks and two stem cell research laboratories.

"This AABB accreditation represents a major accomplishment for Beike and demonstrates its leadership position in China's regenerative medicine sector. It provides Beike a strong platform from which to further develop what we believe will be an increasingly prosperous cord blood stem cell market in China. We are pleased to be providing them our market leading tools to realize their strategy," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

"We are delighted to become the first bank in China to receive AABB accreditation for the processing and storage of cord blood and cord tissue. Our adoption of the AXP and BioArchive technologies is a critical component of our market vision to become the country's technology and quality leader in cord blood processing and storage," said Dr. Shengqin Ye, Chief Executive Officer of Beike.

About ThermoGenesis Corp.

ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP® MarrowXpress® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
+1-916-858-5107, or
ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
2. ThermoGenesis Announces National Institute of Health Grant
3. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
4. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
6. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
7. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
8. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
10. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
11. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):